Troy– Author –
-
China’s Hopstem Biotech Secures Nearly RMB 200 Million in Series C First Close to Advance iPSC Cell Therapy Pipeline Led by hNPC01
Insight, China's Pharmaceutical Industry China Overview China's Hopstem Biotech has completed the first close of nearly RMB 200 million (approximately $27.5 million USD) in Series C funding to advance its iPSC cell therapy pipeline, led ... -
XsellSmart Biopharmaceutical Completes Patient Enrollment in Phase 1 Trial for Universal Cell Therapy XS411 in Parkinson’s-Type Multiple System Atrophy
VCBeat China Overview XsellSmart Biopharmaceutical announced the completion of full participant enrollment in its Phase 1 registrational clinical trial for XS411, a universal cell therapy targeting Parkinson's-type multiple system atroph... -
Chronic Exposure to Chlorate at Regulatory Safety Limits Induces p21/p16-Mediated Neuronal Senescence and Parkinsonian Decline in iPSC-Derived Neurons
PubMed International Overview This research reports that chronic exposure to chlorate at concentrations within regulatory safety limits accelerates neuronal senescence in human iPSC-derived dopaminergic neurons, leading to Parkinsonian-l... -
Intellia Therapeutics Advances CRISPR Gene Therapy Pipeline, Including NTLA-2002 for HAE
Tracxn USA Overview Intellia Therapeutics is a public company advancing therapeutics based on CRISPR/Cas9 technology, with its lead candidate, NTLA-2002, an investigational CRISPR therapy for hereditary angioedema (HAE). The company also... -
Rapid Rise of iPSC-Based Therapies: Manufacturing Challenges and FUJIFILM Cellular Dynamics’ Automation Solutions
Contract Pharma International Overview iPSC-based therapies are rapidly advancing as a renewable, standardized source for allogeneic treatments and scalable solutions across various indications. However, manufacturing poses challenges in... -
Capricor Therapeutics Establishes Commercial Manufacturing for Deramiocel Cell Therapy for DMD, Reports Q2 2026 Financials
Capricor Therapeutics USA Overview Capricor Therapeutics reported its Q2 2026 financial results, highlighting commercial and manufacturing readiness for its lead product candidate, Deramiocel. This allogeneic cardiac-derived cell therapy... -
UC Santa Barbara Researchers Successfully Restore Vision in Two AMD Patients with Stem Cell Retinal Patch
CIRM (California Institute for Regenerative Medicine) UK Overview A stem cell-based retinal patch developed by UC Santa Barbara researchers successfully restored vision in two UK patients suffering from age-related macular degeneration (... -
UCSD Advances Next-Gen CAR-T & Gamma Delta T-Cell Therapies for Solid Tumors in Multiple Phase 1 Clinical Trials
UCSD USA Overview UCSD is actively pursuing multiple Phase 1 clinical trials for next-generation cell therapies targeting advanced solid tumors. Featured trials include FT825/ONO-8250, an off-the-shelf HER2 CAR-T, and A2B395, an allogene... -
Elicera Therapeutics’ CARMA Study Unveils Striking 91% Tumor Response in Relapsed/Refractory B-cell Lymphoma, Including Prior CAR T-Cell Failures
Elicera Therapeutics Sweden Overview Elicera Therapeutics has concluded patient enrollment for the Phase I segment of its CARMA study, evaluating ELC-301 in patients with relapsed or refractory B-cell lymphoma. Interim efficacy data from... -
New CAR-T Engineering Strategies Target Solid Tumor Barriers: Leveraging Real-World Data & Manufacturing Innovations
ecancer International Overview Novel engineering strategies for CAR-T cell therapy against solid tumors are focusing on enhancing T-cell anti-tumor activity and overcoming microenvironmental barriers. Recent clinical results, such as int...
